Most people who want to try a peptide seriously hit the same two walls.
The first wall is the gray market. Forums, anonymous online shops, and overseas sellers will happily send you a vial. What they cannot tell you is what is actually in it. Independent testing has shown mislabeled compounds and contamination in gray-market peptide products. This is not a niche concern. Repeated subcutaneous injection of unknown material carries real risk, and that risk exists entirely apart from whether the compound would have worked if it were real and clean. The gray market is accessible but it is not trustworthy.
The second wall is the conventional clinical path. If you go to your primary care physician with a specific peptide protocol in mind, you will almost certainly be disappointed. This is not because general practitioners are bad doctors. They are trained for breadth: diagnosing across thousands of conditions, recognizing when to refer, managing the population of problems that walk through the door. They are not trained to go deep on a narrow and fast-moving category that most medical schools have not formally taught. Many will not have seen the literature you have read. Some will push back without a strong basis for doing so. The structural problem is that the GP visit is usually the only legitimate door people know how to open, and it is the wrong door for this question. You walk out without a prescription and without a better option.
These are the two choices most people know about. Neither works. The question is what the actual third option is.
Stack is that option. It connects patients with physicians who work in this category: doctors who understand these compounds and can take a serious intake, not a generic telehealth workflow written for something else. Where a prescription is appropriate, one gets written. Fulfillment is the other half of the problem. Stack routes those prescriptions to local American 503A compounding pharmacies that meet our standards for licensing, active-ingredient sourcing, sterility practices, and third-party batch testing. The patient knows which pharmacy filled the order. The compound that arrives was made for them, on American soil, by a pharmacist accountable for what left the building.
Federal law calls what those pharmacies do 503A compounding. A licensed pharmacist prepares a specific formulation against a valid individual prescription. Active pharmaceutical ingredients come from FDA-registered domestic suppliers meeting USP standards. The pharmacy holds a state board license and is subject to inspection. The product is made to your prescription, not manufactured at mass scale, warehoused, and sold as a one-size-fits-all SKU.
It is worth being clear about what this means relative to large pharmaceutical companies. Compounding pharmacies source raw APIs from many of the same FDA-registered domestic suppliers that large manufacturers use. The underlying molecules are the same. What differs is the model: a compounding pharmacy makes a patient-specific preparation, on American soil, under pharmacist liability, against a valid prescription. A large pharmaceutical manufacturer produces at mass scale under a patent monopoly, at a price point that reflects the absence of competition, in a formulation that cannot be adjusted to an individual's needs. Big pharma has every incentive to keep peptide compounds off the compoundable list, and has lobbied accordingly. The effect of that lobbying, where it has succeeded, is to remove a lower-cost, patient-specific, domestically-produced option and replace it with a branded product the patient cannot modify and cannot price-shop.
The pharmacies doing this compounding work are, for the most part, invisible. They are regional operations licensed state by state, without consumer marketing budgets or recognizable names. You cannot find them easily without knowing where to look. The quality and oversight are there. The interface to reach them is not. Stack exists so the clinical path and the compounding path connect in one place instead of requiring luck and legwork.
The case for Stack is not that every peptide in this category has a robust human trial record. Many do not. The case is that if you are going to try one, the option to do it through a physician-guided process, with a compound made at a verified American pharmacy, should exist and should be easy to find. Until now it has not been.
Biological liberty and freedom, in the sense that matters here, is not the freedom to inject whatever shows up in the mail. It is the freedom to pursue physician-guided options through channels that are legitimate, transparent, and grounded in American compounding medicine, without having to choose between a mystery vial and a door that was never designed for you.
Related: Research Glossary, Screening Tool